NASDAQ:CBIO Crescent Biopharma (CBIO) Stock Price, News & Analysis $19.68 +0.27 (+1.39%) Closing price 09/14/2026 04:00 PM EasternExtended Trading$19.68 +0.00 (+0.01%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Crescent Biopharma Stock (NASDAQ:CBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Crescent Biopharma alerts:Sign Up Key Stats Today's Range$19.40▼$20.4050-Day Range$14.47▼$20.8852-Week Range$8.72▼$27.41Volume251,176 shsAverage Volume261,703 shsMarket Capitalization$730.99 millionP/E RatioN/ADividend YieldN/APrice Target$29.60Consensus RatingModerate Buy Company Overview Crescent Biopharma, Inc. (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates. Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources. The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships. Additional reliable public information about its history, geographic operations and executive leadership is limited.AI Generated. May Contain Errors. Read More Crescent Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreCBIO MarketRank™: Crescent Biopharma scored higher than 54% of companies evaluated by MarketBeat, and ranked 483rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingCrescent Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCrescent Biopharma has a consensus price target of $29.60, representing about 50.4% upside from its current price of $19.68.Amount of Analyst CoverageCrescent Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Crescent Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Crescent Biopharma are expected to decrease in the coming year, from ($2.91) to ($3.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crescent Biopharma is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crescent Biopharma is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrescent Biopharma has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Crescent Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.36% of the float of Crescent Biopharma has been sold short.Short Interest Ratio / Days to CoverCrescent Biopharma has a short interest ratio ("days to cover") of 19.91, which indicates bearish sentiment.Change versus previous monthShort interest in Crescent Biopharma has recently decreased by 1.38%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrescent Biopharma does not currently pay a dividend.Dividend GrowthCrescent Biopharma does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.52 News SentimentCrescent Biopharma has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Crescent Biopharma this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Crescent Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Crescent Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,226,126.00 in company stock.Percentage Held by Insiders24.84% of the stock of Crescent Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crescent Biopharma's insider trading history. Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescent Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBIO Stock News HeadlinesCrescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript2 hours ago | seekingalpha.comCrescent's Tumor Treatment Validated by Akeso Trial Results, Wedbush SaysSeptember 14 at 1:48 PM | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 15 at 1:00 AM | InvestorPlace (Ad)Certain Warrants of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026.September 12 at 11:05 PM | marketscreener.comMCrescent Biopharma Announces Grants of Inducement AwardsSeptember 9, 2026 | globenewswire.comCrescent Biopharma Announces September 2026 Investor Conference PresentationsSeptember 3, 2026 | quiverquant.comQCrescent Biopharma to Present at September Investor ConferencesSeptember 3, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)August 5, 2026 | theglobeandmail.comSee More Headlines CBIO Stock Analysis - Frequently Asked Questions How have CBIO shares performed this year? Crescent Biopharma's stock was trading at $11.86 at the start of the year. Since then, CBIO shares have increased by 65.9% and is now trading at $19.68. How were Crescent Biopharma's earnings last quarter? Crescent Biopharma, Inc. (NASDAQ:CBIO) posted its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.00. When did Crescent Biopharma's stock split? Crescent Biopharma's stock reverse split before market open on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Crescent Biopharma IPO? Crescent Biopharma (CBIO) raised $56 million in an initial public offering on Friday, January 10th 2014. The company issued 7,000,000 shares at a price of $8.00 per share. Who are Crescent Biopharma's major shareholders? Crescent Biopharma's top institutional investors include Opaleye Management Inc. (3.55%), BlackRock Inc. (4.61%), Bank of New York Mellon Corp (0.17%) and Stonepine Capital Management LLC (0.11%). Insiders that own company stock include Fairmount Funds Management Llc, Joshua T Brumm, Jonathan Mcneill, Jan Pinkas, Ellie Eunkyung Im, Richard William Scalzo, Barbara Harlin Bispham and Ryan Lynch. View institutional ownership trends. How do I buy shares of Crescent Biopharma? Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Crescent Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV). Company Calendar Last Earnings7/30/2026Today9/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CBIO's financial health is in the Green zone, according to TradeSmith. CBIO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CBIO Previous SymbolNASDAQ:CBIO CIK1253689 Webwww.crescentbiopharma.com Phone(617) 430-5595Fax336-480-2107Employees44Year Founded2003Price Target and Rating Average Price Target for Crescent Biopharma$29.60 High Price Target$35.00 Low Price Target$22.00 Potential Upside/Downside+50.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($6.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$153.94 million Net MarginsN/A Pretax Margin-1,372.75% Return on Equity-101.50% Return on Assets-86.86% Debt Debt-to-Equity RatioN/A Current Ratio9.66 Quick Ratio9.66 Sales & Book Value Annual Sales$11.88 million Price / Sales61.52 Cash FlowN/A Price / Cash FlowN/A Book Value$14.32 per share Price / Book1.37Miscellaneous Outstanding Shares37,144,000Free Float27,917,000Market Cap$730.99 million OptionableNo Data Beta1.24 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CBIO) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CBIO Stock Alerts